首页 > 最新文献

Drug, Healthcare and Patient Safety最新文献

英文 中文
Assessment of Drug Use Pattern Using WHO Core Prescribing Indicators at Outpatient Settings of Governmental Hospitals in Dessie Town. 用世卫组织核心处方指标评价德西镇公立医院门诊用药模式
IF 1.6 Q3 Medicine Pub Date : 2020-11-27 eCollection Date: 2020-01-01 DOI: 10.2147/DHPS.S266749
Getnet Mengistu, Desye Misganaw, Tessema Tsehay, Belete Kassa Alemu, Kassahun Bogale

Background: Enhancing the standards of medical treatment at all levels of the healthcare delivery system can improve the quality of life in developing countries. One method to promote rational drug use is an assessment of drug use pattern based on drug use indicators.

Objective: To evaluate prescription patterns at the outpatient pharmacy of Dessie Referral Hospital and Boru Meda Hospital at Dessie town.

Methods: An institution-based retrospective cross-sectional study was conducted to assess the prescribing patterns in governmental hospitals of Dessie town from April 1 to May 30, 2019. Six hundred eligible prescriptions were selected from each hospital through a systematic random sampling technique.

Results: The result of this study showed that both hospitals used standard prescriptions (100%). Age (99.0%) and name (94.7%) of patients were the most commonly recorded patient information while weight, address of patients and diagnosis were recorded only in 1.1%, 39.2% and 61.3% of the studied prescription papers, respectively. A total 2409 drugs were prescribed in the 1200 prescription papers and the percentage of encounters with injection(s) and antibacterial(s) was 9.0% and 42.6%, respectively. At each hospital, all drugs were prescribed from the Ethiopian essential drug list.

Conclusion: The present study revealed the use of standard presecription papers at both hospitals. None of the patient-related information was completely written in all prescrptions. For drug-related information, only the name of the drug was written in all prescription papers. There is also a significant deviation from the acceptable WHO standard for prescribing antibiotics.

背景:提高各级医疗保健服务系统的医疗水平可以改善发展中国家的生活质量。以用药指标为基础的用药模式评价是促进合理用药的一种方法。目的:评价德西镇德西转诊医院和博鲁梅达医院门诊药房的处方模式。方法:采用基于机构的回顾性横断面研究,对2019年4月1日至5月30日德西镇公立医院的处方模式进行评估。通过系统随机抽样的方法,从各医院抽取符合条件的处方600张。结果:两家医院均采用标准处方(100%)。患者的年龄(99.0%)和姓名(94.7%)是最常记录的患者信息,而体重、患者地址和诊断分别仅占研究处方纸的1.1%、39.2%和61.3%。1200张处方纸共处方2409种药物,与注射剂和抗菌药物的接触率分别为9.0%和42.6%。在每家医院,所有药物都是按照埃塞俄比亚基本药物清单开具的。结论:本研究揭示了两家医院使用标准处方纸的情况。所有处方中都没有完整地写有与患者相关的信息。对于药物相关的信息,所有的处方纸上只写了药物的名称。此外,还存在明显偏离世卫组织可接受的抗生素处方标准的情况。
{"title":"Assessment of Drug Use Pattern Using WHO Core Prescribing Indicators at Outpatient Settings of Governmental Hospitals in Dessie Town.","authors":"Getnet Mengistu,&nbsp;Desye Misganaw,&nbsp;Tessema Tsehay,&nbsp;Belete Kassa Alemu,&nbsp;Kassahun Bogale","doi":"10.2147/DHPS.S266749","DOIUrl":"https://doi.org/10.2147/DHPS.S266749","url":null,"abstract":"<p><strong>Background: </strong>Enhancing the standards of medical treatment at all levels of the healthcare delivery system can improve the quality of life in developing countries. One method to promote rational drug use is an assessment of drug use pattern based on drug use indicators.</p><p><strong>Objective: </strong>To evaluate prescription patterns at the outpatient pharmacy of Dessie Referral Hospital and Boru Meda Hospital at Dessie town.</p><p><strong>Methods: </strong>An institution-based retrospective cross-sectional study was conducted to assess the prescribing patterns in governmental hospitals of Dessie town from April 1 to May 30, 2019. Six hundred eligible prescriptions were selected from each hospital through a systematic random sampling technique.</p><p><strong>Results: </strong>The result of this study showed that both hospitals used standard prescriptions (100%). Age (99.0%) and name (94.7%) of patients were the most commonly recorded patient information while weight, address of patients and diagnosis were recorded only in 1.1%, 39.2% and 61.3% of the studied prescription papers, respectively. A total 2409 drugs were prescribed in the 1200 prescription papers and the percentage of encounters with injection(s) and antibacterial(s) was 9.0% and 42.6%, respectively. At each hospital, all drugs were prescribed from the Ethiopian essential drug list.</p><p><strong>Conclusion: </strong>The present study revealed the use of standard presecription papers at both hospitals. None of the patient-related information was completely written in all prescrptions. For drug-related information, only the name of the drug was written in all prescription papers. There is also a significant deviation from the acceptable WHO standard for prescribing antibiotics.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2020-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0f/f1/dhps-12-237.PMC7708261.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38673659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
A Pharmacist-Driven Intervention Designed to Improve Medication Accuracy in the Outpatient Kidney Transplant Setting. 一个药剂师驱动的干预,旨在提高门诊肾移植的用药准确性。
IF 1.6 Q3 Medicine Pub Date : 2020-11-25 eCollection Date: 2020-01-01 DOI: 10.2147/DHPS.S264022
Elizabeth A Cohen, Danielle McKimmy, Anna Cerilli, Sanjay Kulkarni

Background: Medication errors are one of the leading causes of complications and readmissions in healthcare and stem directly from inadequate medication lists. In transplantation, medication discrepancies can lead to fluctuating levels of immunosuppression, resulting in rejection, infection, or drug toxicity.

Methods: We implemented a pharmacist-driven intervention designed to improve the accuracy of outpatient kidney transplant patients' medication lists in the electronic medical record (EMR). Baseline medication error rates (Phase 1) were collected, and the intervention was a dedicated pharmacist (Phase 2) who performed medication reconciliation with patients. The primary outcome was the percent of patients with inadequate medication reconciliation determined by any one error in medication reconciliation (Phase 1 vs Phase 2). Secondary outcomes included the number of medication errors, of all medications and high-risk medications, identified per patient sample using statistical process control phase analysis.

Results: Pharmacist-driven medication reconciliation significantly reduced medication list discrepancies from 95% to 28% (P<0.05). There were a total of 398 errors in the control group and 49 errors in the intervention group. In addition, there were 73 high-risk medication discrepancies in the control group and three in the intervention group. The total number of medication errors decreased post-intervention with a marked reduction in the variation of control limits (LCL, UCL: phase 1, -34.3, 113.9; phase 2, -7.1, 15.3) and average number of medication errors per sample (phase 1, 39.8; phase 2, 14.1). For high-risk medications, phase analysis demonstrated a marked reduction in control limit variation between phases (LCL, UCL: phase 1, -10.4, 25.0; phase 2, -0.5, 0.7) and average number of medication errors per sample (phase 1, 7.3; phase 2, 0.1).

Discussion: A dedicated pharmacist improved medication list accuracy over conventional practice that utilizes transplant nurses and physicians. Further studies into the cost-effectiveness of this strategy should further justify this approach.

背景:药物错误是医疗保健并发症和再入院的主要原因之一,直接源于不充分的药物清单。在移植中,药物差异可导致免疫抑制水平波动,导致排斥反应、感染或药物毒性。方法:我们实施了一项药剂师驱动的干预措施,旨在提高门诊肾移植患者电子病历(EMR)药物清单的准确性。收集基线用药错误率(第一阶段),干预是由一名专门的药剂师(第二阶段)与患者进行药物调解。主要结局是由药物调节中的任何一个错误确定的药物调节不充分的患者的百分比(第一阶段与第二阶段)。次要结局包括使用统计过程控制阶段分析确定的每个患者样本中所有药物和高危药物的药物错误数量。结果:药剂师驱动的药物协调显著减少了药物清单的差异,从95%到28% (p讨论:专职药剂师比利用移植护士和医生的传统做法提高了药物清单的准确性。对这一战略成本效益的进一步研究应进一步证明这一办法的合理性。
{"title":"A Pharmacist-Driven Intervention Designed to Improve Medication Accuracy in the Outpatient Kidney Transplant Setting.","authors":"Elizabeth A Cohen,&nbsp;Danielle McKimmy,&nbsp;Anna Cerilli,&nbsp;Sanjay Kulkarni","doi":"10.2147/DHPS.S264022","DOIUrl":"https://doi.org/10.2147/DHPS.S264022","url":null,"abstract":"<p><strong>Background: </strong>Medication errors are one of the leading causes of complications and readmissions in healthcare and stem directly from inadequate medication lists. In transplantation, medication discrepancies can lead to fluctuating levels of immunosuppression, resulting in rejection, infection, or drug toxicity.</p><p><strong>Methods: </strong>We implemented a pharmacist-driven intervention designed to improve the accuracy of outpatient kidney transplant patients' medication lists in the electronic medical record (EMR). Baseline medication error rates (Phase 1) were collected, and the intervention was a dedicated pharmacist (Phase 2) who performed medication reconciliation with patients. The primary outcome was the percent of patients with inadequate medication reconciliation determined by any one error in medication reconciliation (Phase 1 vs Phase 2). Secondary outcomes included the number of medication errors, of all medications and high-risk medications, identified per patient sample using statistical process control phase analysis.</p><p><strong>Results: </strong>Pharmacist-driven medication reconciliation significantly reduced medication list discrepancies from 95% to 28% (<i>P</i><0.05). There were a total of 398 errors in the control group and 49 errors in the intervention group. In addition, there were 73 high-risk medication discrepancies in the control group and three in the intervention group. The total number of medication errors decreased post-intervention with a marked reduction in the variation of control limits (LCL, UCL: phase 1, -34.3, 113.9; phase 2, -7.1, 15.3) and average number of medication errors per sample (phase 1, 39.8; phase 2, 14.1). For high-risk medications, phase analysis demonstrated a marked reduction in control limit variation between phases (LCL, UCL: phase 1, -10.4, 25.0; phase 2, -0.5, 0.7) and average number of medication errors per sample (phase 1, 7.3; phase 2, 0.1).</p><p><strong>Discussion: </strong>A dedicated pharmacist improved medication list accuracy over conventional practice that utilizes transplant nurses and physicians. Further studies into the cost-effectiveness of this strategy should further justify this approach.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2020-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/DHPS.S264022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38331435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Effects of Eperisone Hydrochloride and Non-Steroid Anti-Inflammatory Drugs (NSAIDs) for Acute Non-Specific Back Pain with Muscle Spasm: A Prospective, Open-Label Study. 盐酸依培立松和非甾体抗炎药(NSAIDs)治疗急性非特异性腰痛伴肌肉痉挛的疗效:一项前瞻性、开放标签研究
IF 1.6 Q3 Medicine Pub Date : 2020-11-16 eCollection Date: 2020-01-01 DOI: 10.2147/DHPS.S278467
Rizaldy Taslim Pinzon, Vincent Ongko Wijaya, Dessy Paramitha, Raymondus Rangga Bagaskara

Background: Low back pain (LBP) occurs as a common condition and may harm the patient's quality-of-life. Non-steroid anti-inflammatory drugs (NSAIDs) and eperisone form a drug regiment that has been reported as effective in improving low back pain, yet the evidence for its efficacy and safety is lacking.

Objective: The aim of this study was to evaluate the effect of eperisone hydrochloride and ibuprofen compared with ibuprofen alone in reducing symptoms of patients with acute non-specific back pain with a muscle spasm.

Methods: This was an open-label, prospective study involving 100 subjects with symptoms of back pain and muscle spasm. Eligible participants were randomly allocated to an experimental group (54 patients) and a control group (46 patients). The experimental group received eperisone 50 mg three times daily + ibuprofen 400 mg twice daily, and the control group received ibuprofen 400 mg twice daily over a 4-week duration. The primary outcomes were measured with the visual analog scale (VAS), and finger-to-floor (FTF) distance at baseline, week 2, and week 4.

Results: After 4 weeks of follow-up, results from 59 subjects were collected. In both groups, VAS and FTF were decreased compared to baseline. Clinically significant pain reduction (>50% than baseline) was observed to be higher in the experimental group compared with the control group in the fourth week (72.4% vs 46.7%, P<0.05). At the end of the study, pain reduction in the experimental group was more significant compared to the control group (28.13±24.72 vs 34.42±28.47) and participants mobility (FTF distance <10 cm) improved in both groups, especially in the experimental group (75.9% vs 70%). There was no difference in adverse events between groups (P>0.05).

Conclusion: The combination of eperisone hydrochloride and ibuprofen effectively reduces pain and improves functional outcomes over ibuprofen alone with a similar safety profile in these patients with acute non-specific back pain with muscle spasm.

背景:腰痛(LBP)是一种常见的疾病,可能会影响患者的生活质量。非甾体抗炎药(NSAIDs)和依培力松组成了一个药物团,已被报道为有效改善腰痛,但其有效性和安全性的证据缺乏。目的:本研究的目的是评价盐酸依培立松和布洛芬在减轻急性非特异性背部疼痛并肌肉痉挛患者症状方面的效果,并与单独使用布洛芬进行比较。方法:这是一项开放标签的前瞻性研究,涉及100名有背痛和肌肉痉挛症状的受试者。符合条件的参与者被随机分配到实验组(54例)和对照组(46例)。实验组给予依培力松50 mg,每日3次+布洛芬400 mg,每日2次,对照组给予布洛芬400 mg,每日2次,疗程4周。主要结果在基线、第2周和第4周用视觉模拟量表(VAS)和手指到地板的距离(FTF)来测量。结果:随访4周,共收集59例受试者的结果。两组的VAS和FTF均较基线降低。第4周,实验组临床显著性疼痛减轻率(大于基线50%)高于对照组(72.4% vs 46.7%, PP>0.05)。结论:与布洛芬单用相比,盐酸依培立松联合布洛芬可有效减轻急性非特异性腰痛伴肌肉痉挛患者的疼痛,改善功能预后,且安全性相似。
{"title":"Effects of Eperisone Hydrochloride and Non-Steroid Anti-Inflammatory Drugs (NSAIDs) for Acute Non-Specific Back Pain with Muscle Spasm: A Prospective, Open-Label Study.","authors":"Rizaldy Taslim Pinzon,&nbsp;Vincent Ongko Wijaya,&nbsp;Dessy Paramitha,&nbsp;Raymondus Rangga Bagaskara","doi":"10.2147/DHPS.S278467","DOIUrl":"https://doi.org/10.2147/DHPS.S278467","url":null,"abstract":"<p><strong>Background: </strong>Low back pain (LBP) occurs as a common condition and may harm the patient's quality-of-life. Non-steroid anti-inflammatory drugs (NSAIDs) and eperisone form a drug regiment that has been reported as effective in improving low back pain, yet the evidence for its efficacy and safety is lacking.</p><p><strong>Objective: </strong>The aim of this study was to evaluate the effect of eperisone hydrochloride and ibuprofen compared with ibuprofen alone in reducing symptoms of patients with acute non-specific back pain with a muscle spasm.</p><p><strong>Methods: </strong>This was an open-label, prospective study involving 100 subjects with symptoms of back pain and muscle spasm. Eligible participants were randomly allocated to an experimental group (54 patients) and a control group (46 patients). The experimental group received eperisone 50 mg three times daily + ibuprofen 400 mg twice daily, and the control group received ibuprofen 400 mg twice daily over a 4-week duration. The primary outcomes were measured with the visual analog scale (VAS), and finger-to-floor (FTF) distance at baseline, week 2, and week 4.</p><p><strong>Results: </strong>After 4 weeks of follow-up, results from 59 subjects were collected. In both groups, VAS and FTF were decreased compared to baseline. Clinically significant pain reduction (>50% than baseline) was observed to be higher in the experimental group compared with the control group in the fourth week (72.4% vs 46.7%, <i>P</i><0.05). At the end of the study, pain reduction in the experimental group was more significant compared to the control group (28.13±24.72 vs 34.42±28.47) and participants mobility (FTF distance <10 cm) improved in both groups, especially in the experimental group (75.9% vs 70%). There was no difference in adverse events between groups (<i>P</i>>0.05).</p><p><strong>Conclusion: </strong>The combination of eperisone hydrochloride and ibuprofen effectively reduces pain and improves functional outcomes over ibuprofen alone with a similar safety profile in these patients with acute non-specific back pain with muscle spasm.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2020-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/DHPS.S278467","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38643012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Under-Reporting of a Critical Perioperative Adverse Event: Intravenous Infiltration and Extravasation. 严重围手术期不良事件的漏报:静脉浸润和外渗。
IF 1.6 Q3 Medicine Pub Date : 2020-11-13 eCollection Date: 2020-01-01 DOI: 10.2147/DHPS.S271832
George Tewfik

A critical step in understanding and preventing potentially disastrous complications in the perioperative period is the accurate recording of their occurrence and subsequent analysis. However, the recording of intravenous infiltration and extravasation is likely inaccurate due to several factors: rare serious complications associated with infiltration/extravasation, limitation in ICD-10 codes to describe the injury, reliance on coders to record these events in searchable databases, and limited quality measures in anesthesiology to record these events. Although current literature cites results of studies that found rates of 16% and higher for intravenous infiltration, a limited internal review at University Hospital in Newark, NJ found significantly lower rates with only 14 instances recorded in an 18-month period across the institution. This leads the author to conclude that interventions are required to better track these events including such steps as staff education and more efficient/accessible reporting systems. The accurate recording and analyzing of data related to adverse events, and in particular regarding infiltration and extravasation, require revision and reinterpretation to gain an accurate picture of their rates.

了解和预防围手术期潜在的灾难性并发症的关键一步是准确记录其发生和随后的分析。然而,由于以下几个因素,静脉浸润和外渗的记录可能不准确:与浸润/外渗相关的罕见严重并发症,ICD-10编码描述损伤的局限性,依赖编码器在可搜索的数据库中记录这些事件,以及麻醉学记录这些事件的质量措施有限。尽管目前文献引用的研究结果发现静脉浸润率为16%甚至更高,但新泽西州纽瓦克大学医院的一项有限的内部审查发现,该机构在18个月内仅记录了14例静脉浸润率明显较低。这使作者得出结论,需要采取干预措施,以便更好地跟踪这些事件,包括工作人员教育和更有效/更容易使用的报告系统等步骤。准确记录和分析与不良事件有关的数据,特别是关于浸润和外渗的数据,需要修订和重新解释,以获得其发生率的准确情况。
{"title":"Under-Reporting of a Critical Perioperative Adverse Event: Intravenous Infiltration and Extravasation.","authors":"George Tewfik","doi":"10.2147/DHPS.S271832","DOIUrl":"https://doi.org/10.2147/DHPS.S271832","url":null,"abstract":"<p><p>A critical step in understanding and preventing potentially disastrous complications in the perioperative period is the accurate recording of their occurrence and subsequent analysis. However, the recording of intravenous infiltration and extravasation is likely inaccurate due to several factors: rare serious complications associated with infiltration/extravasation, limitation in ICD-10 codes to describe the injury, reliance on coders to record these events in searchable databases, and limited quality measures in anesthesiology to record these events. Although current literature cites results of studies that found rates of 16% and higher for intravenous infiltration, a limited internal review at University Hospital in Newark, NJ found significantly lower rates with only 14 instances recorded in an 18-month period across the institution. This leads the author to conclude that interventions are required to better track these events including such steps as staff education and more efficient/accessible reporting systems. The accurate recording and analyzing of data related to adverse events, and in particular regarding infiltration and extravasation, require revision and reinterpretation to gain an accurate picture of their rates.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2020-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/0e/dhps-12-217.PMC7671479.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38630271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database. 利用日本不良药物事件报告数据库对日本依曲单抗相关脑膜炎球菌病进行风险分析
IF 1.6 Q3 Medicine Pub Date : 2020-11-10 eCollection Date: 2020-01-01 DOI: 10.2147/DHPS.S257009
Yumi Matsumura

Purpose: Eculizumab, a drug that blocks activation of the terminal complement pathway, is useful in the treatment of several rare diseases. However, eculizumab-related meningococcal disease is a serious problem. Because of the difficulty diagnosing meningococcal disease, deaths from meningococcal disease may have been overlooked. The purpose of this study was to clarify the trend of meningococcal infection in patients on eculizumab and to evaluate the effectiveness of risk communication.

Methods: Pharmacovigilance analysis was conducted using the Japanese Adverse Drug Event Report database between the first quarter of 2010 and the second quarter of 2019. Of the reports of deaths, those with adverse event terms of fever, shock, altered state of consciousness, loss of consciousness, sepsis, organ failure, and disseminated intravascular coagulation were analyzed as deaths with suspected meningococcal infection.

Results: Of the 3559.2 person-years of eculizumab-exposed patients, 17 patients died with symptoms of meningococcal disease (including two confirmed cases). The mortality rate of meningococcal disease in patients exposed to eculizumab in Japan was estimated to be 0.56 (confirmed cases) to 4.8 (suspected cases) per 1000 person-years. Based on data from the National Epidemiological Surveillance of Infectious Disease, the mortality rate of meningococcal disease in the general population in Japan is 0.0042 per 100,000 person-years. Thus, the mortality rate from meningococcal disease in eculizumab-exposed patients is estimated to be 13,000 to 114,000 times the mortality rate from meningococcal disease in the general population of Japan. Academic societies warned of deaths from meningococcal disease in the first quarter of 2018, calling for appropriate action. Thereafter, only one death with symptoms of meningococcal disease has been reported.

Conclusion: The analysis of the database showed that death from meningococcal disease in eculizumab-exposed individuals may occur more often than expected. This study also showed that appropriate risk communication reduced the fatality rate of meningococcal disease.

目的:Eculizumab是一种阻断终末补体通路激活的药物,可用于治疗几种罕见疾病。然而,异珠单抗相关的脑膜炎球菌病是一个严重的问题。由于脑膜炎球菌病的诊断困难,脑膜炎球菌病造成的死亡可能被忽视。本研究的目的是阐明使用eculizumab的患者脑膜炎球菌感染的趋势,并评估风险沟通的有效性。方法:利用2010年第一季度至2019年第二季度日本药品不良事件报告数据库进行药物警戒分析。在死亡报告中,伴有发热、休克、意识状态改变、意识丧失、败血症、器官衰竭和弥散性血管内凝血等不良事件的死亡报告被分析为疑似脑膜炎球菌感染的死亡。结果:在暴露于eculizumab的3559.2人年患者中,17例患者死于脑膜炎球菌病症状(包括2例确诊病例)。在日本,暴露于eculizumab的患者中脑膜炎球菌病的死亡率估计为每1000人年0.56(确诊病例)至4.8(疑似病例)。根据国家传染病流行病学监测的数据,日本普通人群中脑膜炎球菌病的死亡率为每10万人年0.0042人。因此,在接触异珠单抗的患者中,脑膜炎球菌病的死亡率估计是日本一般人群中脑膜炎球菌病死亡率的1.3万至11.4万倍。各学术团体就2018年第一季度脑膜炎球菌病死亡发出警告,呼吁采取适当行动。此后,仅报告一人因脑膜炎球菌病症状死亡。结论:对数据库的分析表明,暴露于异珠单抗的个体因脑膜炎球菌病死亡的发生率可能高于预期。该研究还表明,适当的风险沟通可降低脑膜炎球菌病的死亡率。
{"title":"Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database.","authors":"Yumi Matsumura","doi":"10.2147/DHPS.S257009","DOIUrl":"https://doi.org/10.2147/DHPS.S257009","url":null,"abstract":"<p><strong>Purpose: </strong>Eculizumab, a drug that blocks activation of the terminal complement pathway, is useful in the treatment of several rare diseases. However, eculizumab-related meningococcal disease is a serious problem. Because of the difficulty diagnosing meningococcal disease, deaths from meningococcal disease may have been overlooked. The purpose of this study was to clarify the trend of meningococcal infection in patients on eculizumab and to evaluate the effectiveness of risk communication.</p><p><strong>Methods: </strong>Pharmacovigilance analysis was conducted using the Japanese Adverse Drug Event Report database between the first quarter of 2010 and the second quarter of 2019. Of the reports of deaths, those with adverse event terms of fever, shock, altered state of consciousness, loss of consciousness, sepsis, organ failure, and disseminated intravascular coagulation were analyzed as deaths with suspected meningococcal infection.</p><p><strong>Results: </strong>Of the 3559.2 person-years of eculizumab-exposed patients, 17 patients died with symptoms of meningococcal disease (including two confirmed cases). The mortality rate of meningococcal disease in patients exposed to eculizumab in Japan was estimated to be 0.56 (confirmed cases) to 4.8 (suspected cases) per 1000 person-years. Based on data from the National Epidemiological Surveillance of Infectious Disease, the mortality rate of meningococcal disease in the general population in Japan is 0.0042 per 100,000 person-years. Thus, the mortality rate from meningococcal disease in eculizumab-exposed patients is estimated to be 13,000 to 114,000 times the mortality rate from meningococcal disease in the general population of Japan. Academic societies warned of deaths from meningococcal disease in the first quarter of 2018, calling for appropriate action. Thereafter, only one death with symptoms of meningococcal disease has been reported.</p><p><strong>Conclusion: </strong>The analysis of the database showed that death from meningococcal disease in eculizumab-exposed individuals may occur more often than expected. This study also showed that appropriate risk communication reduced the fatality rate of meningococcal disease.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2020-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/DHPS.S257009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38623088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Chemotherapy-Related Adverse Drug Reaction and Associated Factors Among Hospitalized Paediatric Cancer Patients at Hospitals in North-West Ethiopia. 埃塞俄比亚西北部医院住院儿科癌症患者化疗相关药物不良反应及相关因素
IF 1.6 Q3 Medicine Pub Date : 2020-11-03 eCollection Date: 2020-01-01 DOI: 10.2147/DHPS.S254644
Gashaw Workalemahu, Ousman Abubeker Abdela, Melaku Kindie Yenit

Background: One of the prevalent treatment modalities for cancer is chemotherapy. Adverse drug reactions, however, are becoming the world's major public health problem. More than half (54.5 percent) of cancer patients need hospitalization for further management, in addition to the increased health-care costs of treatment. The aim of this study was to evaluate adverse drug reactions associated with chemotherapy and related factors in hospitalized paediatric cancer patients in Ethiopia's north-west hospitals.

Methods: From July 1, 2017, to August 13, 2019, a cross-sectional study was carried out among 311 paediatric cancer patients at Gondar Comprehensive University, Specialized Hospital and Felegehiwot referral hospital. The data were entered into Epi Info version 7 and exported for further analysis to Statistical Product and Service Solutions (SPSS). To identify associated variables, both the bi-variate and multi-variate logistic regression analyses were computed. Variables with a P-value of less than 0.05 were considered statistically significant in the multivariate logistic regression analysis.

Results: The overall adverse drug reaction in this study was 41.5 percent ((95% CI: 35.8-47.2%)). Patients who received concomitant medications were at higher risk of experiencing adverse drug reactions (AOR: 2.60 (95% CI: 1.54-4.40)), according to the multivariate logistic regression analysis. Similarly, there was a risk of developing adverse drug reactions in patients taking four or more chemotherapy agents (AOR: 2.67 (95% CI: 1.52-4.68)). In addition, regimens based on etoposide (AOR: 1.99 (95% CI: 0.93-4.27)), mercaptopurine (AOR: 3.91 (95% CI: 1.06-14.46)) and doxorubicin (AOR: 2.32 (95% CI: 1.30-4.15)) were at higher risk for adverse drug reactions in patients.

Conclusion: Adverse drug reactions developed in a significant proportion of the study patients (2 out of 5 patients). Therefore, for pediatric cancer patients on concomitant medications and for patients on etoposide, mercaptopurine and doxorubicin drug regimens, efficient prevention and management of adverse drug reactions should be sought.

背景:化疗是癌症的主要治疗方式之一。然而,药物不良反应正在成为世界上主要的公共卫生问题。超过一半(54.5%)的癌症患者需要住院接受进一步治疗,除此之外,治疗的保健费用也在增加。本研究的目的是评估埃塞俄比亚西北部医院住院儿科癌症患者与化疗相关的药物不良反应及其相关因素。方法:2017年7月1日至2019年8月13日,对贡达尔综合大学专科医院和Felegehiwot转诊医院311例儿科癌症患者进行横断面研究。将数据输入Epi Info version 7,并导出到SPSS(统计产品和服务解决方案)进行进一步分析。为了确定相关变量,计算了双变量和多变量逻辑回归分析。在多因素logistic回归分析中,p值小于0.05的变量被认为具有统计学意义。结果:本组总不良反应发生率为41.5% (95% CI: 35.8 ~ 47.2%)。根据多因素logistic回归分析,接受联合用药的患者发生药物不良反应的风险更高(AOR: 2.60 (95% CI: 1.54-4.40))。同样,服用四种或四种以上化疗药物的患者也有发生药物不良反应的风险(AOR: 2.67 (95% CI: 1.52-4.68))。此外,基于依托泊苷(AOR: 1.99 (95% CI: 0.93-4.27))、巯基嘌呤(AOR: 3.91 (95% CI: 1.06-14.46))和阿霉素(AOR: 2.32 (95% CI: 1.30-4.15))的方案在患者中发生药物不良反应的风险更高。结论:5例患者中有2例出现药物不良反应。因此,对于联合用药的儿童癌症患者,以及依托泊苷、巯基嘌呤和阿霉素联合用药的儿童癌症患者,应寻求有效的药物不良反应的预防和管理。
{"title":"Chemotherapy-Related Adverse Drug Reaction and Associated Factors Among Hospitalized Paediatric Cancer Patients at Hospitals in North-West Ethiopia.","authors":"Gashaw Workalemahu, Ousman Abubeker Abdela, Melaku Kindie Yenit","doi":"10.2147/DHPS.S254644","DOIUrl":"10.2147/DHPS.S254644","url":null,"abstract":"<p><strong>Background: </strong>One of the prevalent treatment modalities for cancer is chemotherapy. Adverse drug reactions, however, are becoming the world's major public health problem. More than half (54.5 percent) of cancer patients need hospitalization for further management, in addition to the increased health-care costs of treatment. The aim of this study was to evaluate adverse drug reactions associated with chemotherapy and related factors in hospitalized paediatric cancer patients in Ethiopia's north-west hospitals.</p><p><strong>Methods: </strong>From July 1, 2017, to August 13, 2019, a cross-sectional study was carried out among 311 paediatric cancer patients at Gondar Comprehensive University, Specialized Hospital and Felegehiwot referral hospital. The data were entered into Epi Info version 7 and exported for further analysis to Statistical Product and Service Solutions (SPSS). To identify associated variables, both the bi-variate and multi-variate logistic regression analyses were computed. Variables with a P-value of less than 0.05 were considered statistically significant in the multivariate logistic regression analysis.</p><p><strong>Results: </strong>The overall adverse drug reaction in this study was 41.5 percent ((95% CI: 35.8-47.2%)). Patients who received concomitant medications were at higher risk of experiencing adverse drug reactions (AOR: 2.60 (95% CI: 1.54-4.40)), according to the multivariate logistic regression analysis. Similarly, there was a risk of developing adverse drug reactions in patients taking four or more chemotherapy agents (AOR: 2.67 (95% CI: 1.52-4.68)). In addition, regimens based on etoposide (AOR: 1.99 (95% CI: 0.93-4.27)), mercaptopurine (AOR: 3.91 (95% CI: 1.06-14.46)) and doxorubicin (AOR: 2.32 (95% CI: 1.30-4.15)) were at higher risk for adverse drug reactions in patients.</p><p><strong>Conclusion: </strong>Adverse drug reactions developed in a significant proportion of the study patients (2 out of 5 patients). Therefore, for pediatric cancer patients on concomitant medications and for patients on etoposide, mercaptopurine and doxorubicin drug regimens, efficient prevention and management of adverse drug reactions should be sought.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2020-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/DHPS.S254644","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38591950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
The Prevalence of Needlesticks and Sharp Injuries, and the Associated Factors Among Midwives and Nurses in North Wollo Zone Public Hospitals, North East Ethiopia: An Institution-based Cross-sectional Study. 埃塞俄比亚东北部北沃罗区公立医院助产士和护士中针刺和锐器伤害的流行及其相关因素:一项基于机构的横断面研究。
IF 1.6 Q3 Medicine Pub Date : 2020-10-15 eCollection Date: 2020-01-01 DOI: 10.2147/DHPS.S273669
Addisu Getie, Adam Wondmieneh, Getachew Tesfaw

Background: Health professionals are at high risk of exposure for needlestick or sharp injury due to repeated exposure in clinical areas. This exposure leads to the acquiring of different infectious diseases like human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and other infectious diseases. Nurses and midwives having repeated exposure due to long working time, not wearing personal protective equipment, less work experience, and who are unable to apply infection prevention utilization guidelines are at high risk of needlestick and sharp injuries.

Methods: An institutional-based, cross-sectional study design was conducted in North Wollo Zone public hospitals. A simple random sampling technique was applied to select study subjects. The method of data collection was self-administered questionnaires that are structured and pretested from February to March 2019. The data were analyzed using both descriptive and analytical statistics. Binary logistic regressions were used to test the association between variables. Then, P-value <0.05 was considered as statistically significant in this study.

Results: Of the 147 respondents who participated in the study, 50.3% were female and 49.7% were male. The prevalence of needlestick and the sharp injuries was 75.5%. Recap practice of needle (AOR: 3.880; 95%CI: 1.666-9.036), working room (maternal care room) (AOR: 2.968; 95%CI: 1.012-8.703), and contagious room like emergency room (AOR: 3.587; 95%CI: 1.383-9.301) are significantly associated with needlestick and sharp injuries.

Conclusion: This study showed that three-quarters of the study subjects were exposed to needlestick injury at least once in the past year. Needle recapping practice and working room were associated with needlestick and sharp injuries. Then, health personnel should avoid the practice of recapping a needle and tale care themself to avoid needle and sharp injuries in the workplace.

背景:卫生专业人员由于在临床领域的反复接触,具有较高的针刺或锐器伤害暴露风险。这种暴露会导致感染不同的传染病,如人类免疫缺陷病毒(HIV)、乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)和其他传染病。由于工作时间长、未穿戴个人防护装备、工作经验少以及无法应用感染预防使用指南而反复接触的护士和助产士是刺伤和锐器伤的高危人群。方法:在北沃罗区公立医院进行了一项基于机构的横断面研究设计。采用简单的随机抽样方法选择研究对象。数据收集方法为自填问卷,于2019年2月至3月进行结构化和预测试。使用描述性统计和分析性统计对数据进行分析。使用二元逻辑回归来检验变量之间的相关性。然后,p值结果:147名参与研究的受访者中,50.3%为女性,49.7%为男性。针刺和锐器伤的发生率为75.5%。针管实习总结(AOR: 3.880;95%CI: 1.666-9.036)、工作间(产妇护理室)(AOR: 2.968;95%CI: 1.012-8.703),传染室如急诊室(AOR: 3.587;95%CI: 1.383-9.301)与针刺和锐器伤显著相关。结论:本研究表明,四分之三的研究对象在过去一年中至少接触过一次针刺伤。针套练习和工作间与针刺和锐器伤有关。然后,卫生人员应避免重新包扎针头的做法,并注意自己,以避免在工作场所受到针和锐器伤害。
{"title":"The Prevalence of Needlesticks and Sharp Injuries, and the Associated Factors Among Midwives and Nurses in North Wollo Zone Public Hospitals, North East Ethiopia: An Institution-based Cross-sectional Study.","authors":"Addisu Getie,&nbsp;Adam Wondmieneh,&nbsp;Getachew Tesfaw","doi":"10.2147/DHPS.S273669","DOIUrl":"https://doi.org/10.2147/DHPS.S273669","url":null,"abstract":"<p><strong>Background: </strong>Health professionals are at high risk of exposure for needlestick or sharp injury due to repeated exposure in clinical areas. This exposure leads to the acquiring of different infectious diseases like human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and other infectious diseases. Nurses and midwives having repeated exposure due to long working time, not wearing personal protective equipment, less work experience, and who are unable to apply infection prevention utilization guidelines are at high risk of needlestick and sharp injuries.</p><p><strong>Methods: </strong>An institutional-based, cross-sectional study design was conducted in North Wollo Zone public hospitals. A simple random sampling technique was applied to select study subjects. The method of data collection was self-administered questionnaires that are structured and pretested from February to March 2019. The data were analyzed using both descriptive and analytical statistics. Binary logistic regressions were used to test the association between variables. Then, <i>P</i>-value <0.05 was considered as statistically significant in this study.</p><p><strong>Results: </strong>Of the 147 respondents who participated in the study, 50.3% were female and 49.7% were male. The prevalence of needlestick and the sharp injuries was 75.5%. Recap practice of needle (AOR: 3.880; 95%CI: 1.666-9.036), working room (maternal care room) (AOR: 2.968; 95%CI: 1.012-8.703), and contagious room like emergency room (AOR: 3.587; 95%CI: 1.383-9.301) are significantly associated with needlestick and sharp injuries.</p><p><strong>Conclusion: </strong>This study showed that three-quarters of the study subjects were exposed to needlestick injury at least once in the past year. Needle recapping practice and working room were associated with needlestick and sharp injuries. Then, health personnel should avoid the practice of recapping a needle and tale care themself to avoid needle and sharp injuries in the workplace.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2020-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/DHPS.S273669","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38539076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Burden of Healthcare-Associated Infections and Associated Risk Factors at Adama Hospital Medical College, Adama, Oromia, Ethiopia. 埃塞俄比亚奥罗米亚阿达玛阿达玛医院医学院的医疗保健相关感染负担和相关风险因素
IF 1.6 Q3 Medicine Pub Date : 2020-10-14 eCollection Date: 2020-01-01 DOI: 10.2147/DHPS.S251827
Adinew Zewdu Chernet, Kassu Dasta, Feleke Belachew, Baharu Zewdu, Mengistu Melese, Musa Mohammed Ali

Introduction: Healthcare-associated infection (HCAI) is a type of infection that is acquired while receiving healthcare services in a hospital or other healthcare settings. The objective of this study was to determine the incidence of HCAI and associated factors at Adama Hospital Medical College (AHMC), Adama city, Ethiopia.

Method: A hospital-based longitudinal study was conducted among 300 participants at AHMC from February to May 2017. The study participants' clinical characteristics were collected using a structured interview and clinical evaluations. Data were analyzed by descriptive statistics using SPSS software version 20. Various clinical samples collected from participants were processed and bacteria were isolated by using standard microbiological methods recommended by the World Health Organization.

Result: The total incidence rate of HCAI was 9.7 [95% CI: 7.1-12.9] cases per 1000 persons-days. Specific incidence rates were as follows: 8 cases per 1000 person-days [95% CI: 08.74, 20.66] for surgical site infections; 60.2 cases per 1000 device-days [95% CI: 33.47, 100.3] for catheter-associated urinary tract infections; 1.4 cases per 1000 device-days [95% CI: 0.06752, 6.656] for catheter-associated bloodstream infections; 14.1 cases per 1000 device-days [95% CI: 0.7047, 69.46] for ventilator-associated pneumonia; 73.5 cases per 1000 person-days [95% CI: 26.94, 163] for non-surgical skin break infections and 0.6 cases per 1000 person-days [95% CI: 0.02906, 2.864] for antibiotic-associated diarrhea. Most of the infections were caused by Gram-negative bacteria. Renal disease and type 2 diabetes mellitus were significantly associated with HCAI (P<0.05).

Conclusion: HCAI was predominant in this study. The major contributing factors for HCAI at AHMC were renal disease and type 2diabetes mellitus.

医疗保健相关感染(HCAI)是在医院或其他医疗保健机构接受医疗保健服务时获得的一种感染。本研究的目的是确定埃塞俄比亚阿达玛市阿达玛医院医学院(AHMC)的HCAI发生率及其相关因素。方法:于2017年2月至5月对AHMC的300名参与者进行了以医院为基础的纵向研究。通过结构化访谈和临床评估收集研究参与者的临床特征。数据采用SPSS软件20版进行描述性统计。利用世界卫生组织推荐的标准微生物学方法,对从参与者身上收集的各种临床样本进行了处理,并分离了细菌。结果:HCAI总发病率为9.7例/ 1000人-天[95% CI: 7.1 ~ 12.9]。具体发生率如下:手术部位感染8例/ 1000人天[95% CI: 08.74, 20.66];导尿管相关尿路感染60.2例/ 1000器械日[95% CI: 33.47, 100.3];导管相关血流感染1.4例/ 1000器械日[95% CI: 0.06752, 6.656];呼吸机相关肺炎14.1例/ 1000器械日[95% CI: 0.7047, 69.46];非手术性皮肤破损感染为73.5例/ 1000人日[95% CI: 26.94, 163],抗生素相关性腹泻为0.6例/ 1000人日[95% CI: 0.02906, 2.864]。大多数感染是由革兰氏阴性菌引起的。肾脏疾病和2型糖尿病与HCAI有显著相关性(结论:HCAI在本研究中占主导地位。AHMC患者HCAI的主要影响因素是肾脏疾病和2型糖尿病。
{"title":"Burden of Healthcare-Associated Infections and Associated Risk Factors at Adama Hospital Medical College, Adama, Oromia, Ethiopia.","authors":"Adinew Zewdu Chernet, Kassu Dasta, Feleke Belachew, Baharu Zewdu, Mengistu Melese, Musa Mohammed Ali","doi":"10.2147/DHPS.S251827","DOIUrl":"10.2147/DHPS.S251827","url":null,"abstract":"<p><strong>Introduction: </strong>Healthcare-associated infection (HCAI) is a type of infection that is acquired while receiving healthcare services in a hospital or other healthcare settings. The objective of this study was to determine the incidence of HCAI and associated factors at Adama Hospital Medical College (AHMC), Adama city, Ethiopia.</p><p><strong>Method: </strong>A hospital-based longitudinal study was conducted among 300 participants at AHMC from February to May 2017. The study participants' clinical characteristics were collected using a structured interview and clinical evaluations. Data were analyzed by descriptive statistics using SPSS software version 20. Various clinical samples collected from participants were processed and bacteria were isolated by using standard microbiological methods recommended by the World Health Organization.</p><p><strong>Result: </strong>The total incidence rate of HCAI was 9.7 [95% CI: 7.1-12.9] cases per 1000 persons-days. Specific incidence rates were as follows: 8 cases per 1000 person-days [95% CI: 08.74, 20.66] for surgical site infections; 60.2 cases per 1000 device-days [95% CI: 33.47, 100.3] for catheter-associated urinary tract infections; 1.4 cases per 1000 device-days [95% CI: 0.06752, 6.656] for catheter-associated bloodstream infections; 14.1 cases per 1000 device-days [95% CI: 0.7047, 69.46] for ventilator-associated pneumonia; 73.5 cases per 1000 person-days [95% CI: 26.94, 163] for non-surgical skin break infections and 0.6 cases per 1000 person-days [95% CI: 0.02906, 2.864] for antibiotic-associated diarrhea. Most of the infections were caused by Gram-negative bacteria. Renal disease and type 2 diabetes mellitus were significantly associated with HCAI (P<0.05).</p><p><strong>Conclusion: </strong>HCAI was predominant in this study. The major contributing factors for HCAI at AHMC were renal disease and type 2diabetes mellitus.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2020-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/da/dhps-12-177.PMC7569037.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38539075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Evaluation of Antibiotic Utilization Pattern During Acute Diarrheal Disease at Chefa-Robit Health Center, Kemissie, North East Amhara, Ethiopia. 埃塞俄比亚阿姆哈拉东北部肯米西chea - robit卫生中心急性腹泻病期间抗生素使用模式的评估
IF 1.6 Q3 Medicine Pub Date : 2020-09-28 eCollection Date: 2020-01-01 DOI: 10.2147/DHPS.S256330
Desye Misganaw, Kassaw Abtew

Background: Despite the fact that the majority of the acute diarrheal diseases are viral in origin and self-limited, routine and injudicious antibiotic treatment is a common practice globally and more prevalent in Africa. Indeed, the irrational use of antibiotics has a detrimental effect on the issue of antibiotics resistance and associated healthcare costs. Accordingly, a health center-based cross-sectional study is mandatory and was conducted due to the common malpractice of antibiotics use.

Objective: The aim of this study was to evaluate the antibiotic use pattern in the treatment of acute diarrheal disease in Chefa-robit health center, Kemissie, Northeastern Ethiopia.

Methods and materials: A retrospective cross-sectional study was conducted to evaluate the antibiotic utilization pattern for the treatment of acute diarrheal disease. Data was collected from 230 patients' record cards treated for acute diarrheal disease from January 2018 to December 2018 using structured questionnaires. The finding is presented using frequency distribution and percentages in tables as well as figures.

Results: Among the 230 patients, 49.60% were males and the rest were females. From the total, 172 of them were with watery type of diarrhea and 132 of them were prescribed antibiotics inappropriately out of which 77 were under 5 years. In addition, 27 patients were diagnosed with mucoid diarrhea and only eight of them were treated with antibiotics whereas 31 patients were with bloody type of diarrhea and 10 of them were not treated with antibiotics. Of the 230 cases, 161 (70%) patients received different types of antibiotics, and co-trimoxazole, amoxicillin and ciprofloxacin were the most prescribed antibiotics.

Conclusion: The study revealed that there is a high level of inappropriate antibiotics use which may fuel the increased antimicrobial resistance and associated costs nationally as well as globally.

背景:尽管大多数急性腹泻疾病是由病毒引起的,而且是自限性的,但常规和不明智的抗生素治疗是全球普遍的做法,在非洲更为普遍。事实上,抗生素的不合理使用对抗生素耐药性问题和相关的医疗费用产生了不利影响。因此,基于卫生中心的横断面研究是强制性的,并且由于抗生素使用的常见弊端而进行了研究。目的:了解埃塞俄比亚东北部肯米西市Chefa-robit卫生中心治疗急性腹泻的抗生素使用情况。方法与材料:采用回顾性横断面研究评价急性腹泻病的抗生素使用模式。数据收集自2018年1月至2018年12月230例急性腹泻病患者的病历卡,采用结构化问卷调查。这一发现是用频率分布和表格中的百分比以及图表来表示的。结果:230例患者中男性占49.60%,其余为女性。其中,水样腹泻172例,抗生素使用不当132例,其中5岁以下77例。此外,27例患者诊断为粘液样腹泻,其中只有8例患者接受了抗生素治疗,而31例患者为血性腹泻,其中10例患者未接受抗生素治疗。在230例患者中,有161例(70%)患者使用了不同类型的抗生素,其中复方新诺明、阿莫西林和环丙沙星是处方最多的抗生素。结论:该研究表明,不适当使用抗生素的情况很高,这可能会加剧国家和全球抗菌素耐药性和相关费用的增加。
{"title":"Evaluation of Antibiotic Utilization Pattern During Acute Diarrheal Disease at Chefa-Robit Health Center, Kemissie, North East Amhara, Ethiopia.","authors":"Desye Misganaw, Kassaw Abtew","doi":"10.2147/DHPS.S256330","DOIUrl":"10.2147/DHPS.S256330","url":null,"abstract":"<p><strong>Background: </strong>Despite the fact that the majority of the acute diarrheal diseases are viral in origin and self-limited, routine and injudicious antibiotic treatment is a common practice globally and more prevalent in Africa. Indeed, the irrational use of antibiotics has a detrimental effect on the issue of antibiotics resistance and associated healthcare costs. Accordingly, a health center-based cross-sectional study is mandatory and was conducted due to the common malpractice of antibiotics use.</p><p><strong>Objective: </strong>The aim of this study was to evaluate the antibiotic use pattern in the treatment of acute diarrheal disease in Chefa-robit health center, Kemissie, Northeastern Ethiopia.</p><p><strong>Methods and materials: </strong>A retrospective cross-sectional study was conducted to evaluate the antibiotic utilization pattern for the treatment of acute diarrheal disease. Data was collected from 230 patients' record cards treated for acute diarrheal disease from January 2018 to December 2018 using structured questionnaires. The finding is presented using frequency distribution and percentages in tables as well as figures.</p><p><strong>Results: </strong>Among the 230 patients, 49.60% were males and the rest were females. From the total, 172 of them were with watery type of diarrhea and 132 of them were prescribed antibiotics inappropriately out of which 77 were under 5 years. In addition, 27 patients were diagnosed with mucoid diarrhea and only eight of them were treated with antibiotics whereas 31 patients were with bloody type of diarrhea and 10 of them were not treated with antibiotics. Of the 230 cases, 161 (70%) patients received different types of antibiotics, and co-trimoxazole, amoxicillin and ciprofloxacin were the most prescribed antibiotics.</p><p><strong>Conclusion: </strong>The study revealed that there is a high level of inappropriate antibiotics use which may fuel the increased antimicrobial resistance and associated costs nationally as well as globally.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2020-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/e7/dhps-12-169.PMC7534044.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38494245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Drug Use Evaluation of Ceftriaxone in Ras-Desta Memorial General Hospital, Ethiopia. 埃塞俄比亚Ras-Desta纪念总医院头孢曲松用药评价
IF 1.6 Q3 Medicine Pub Date : 2020-09-10 eCollection Date: 2020-01-01 DOI: 10.2147/DHPS.S260364
Oumer Sada Muhammed, Beshir Bedru Nasir

Background: Ceftriaxone is one of the most commonly used antibiotics due to its availability, wide spectrum of activity and low toxicity. However, irrational use of ceftriaxone is one of the current issues in most countries, especially developing ones.

Objective: The aim of this study was to evaluate ceftriaxone utilization in different wards of Ras-Desta Memorial General Hospital (RDMGH) in Ethiopia.

Methods: An institution-based retrospective cross-sectional study was conducted on randomly selected 1,079 patients who were admitted to RDMGH from May 2017 to April 2018. A structured data abstraction format was used to collect data from patients' medical chart. Micromedex® drug interaction checker was used to identify significant drug-drug interactions, and national and international guidelines were used to evaluate the appropriateness of ceftriaxone use. The data were analyzed by using SPSS version 20.0.

Results: Among the 1,079 patients enrolled, ceftriaxone was utilized by 601 (55.7%) patients, and these patients were considered for evaluation of appropriateness and subsequent analysis. Among 601 patients, ceftriaxone was used for therapeutic purpose in 362 (60.2%) patients; of which, 359 (99.2%) were for empiric therapy and the rest 239 (39.8%) were for prophylaxis. In the majority of the patients, the dose of ceftriaxone was 2g/day 472 (78.6%) and for a duration of 2-7 days 409 (68.1%). Inappropriate use of ceftriaxone was observed among 237 (39.4%) patients with regard to indication, dose/frequency and duration. About half (49.3%) of the deviation from the guidelines was observed from surgical and gynecologic/obstetrics wards. Among the co-prescribed medications with ceftriaxone, ringer lactate, warfarin and heparin were found to have a significant drug-drug interaction.

Conclusion: This study revealed that inappropriate use of ceftriaxone was high in RDMGH. This may increase the emergence of resistant pathogens which may lead to treatment failure and increase cost of therapy. Therefore, adherence to current evidence-based guidelines is recommended.

背景:头孢曲松因其可获得性、广谱活性和低毒性而成为最常用的抗生素之一。然而,头孢曲松的不合理使用是目前大多数国家,特别是发展中国家普遍存在的问题之一。目的:本研究的目的是评估头孢曲松在埃塞俄比亚Ras-Desta纪念总医院(RDMGH)不同病房的使用情况。方法:随机选择2017年5月至2018年4月在RDMGH住院的1079例患者进行基于机构的回顾性横断面研究。采用结构化数据抽象格式从患者病历中收集数据。使用Micromedex®药物相互作用检测器识别显著的药物-药物相互作用,并使用国家和国际指南评估头孢曲松使用的适宜性。采用SPSS 20.0版本对数据进行分析。结果:纳入的1079例患者中,601例(55.7%)患者使用头孢曲松,这些患者被考虑进行适当性评估和后续分析。601例患者中,362例(60.2%)患者使用头孢曲松作为治疗目的;其中经验性治疗359例(99.2%),预防性治疗239例(39.8%)。在大多数患者中,头孢曲松的剂量为2g/天472(78.6%),持续时间为2-7天409(68.1%)。237例(39.4%)患者在适应证、剂量/频率和持续时间方面存在不适当使用头孢曲松的情况。大约一半(49.3%)的偏离指南发生在外科和妇产科病房。在与头孢曲松合用的药物中,乳酸林格、华法林和肝素存在显著的药物相互作用。结论:本研究揭示了头孢曲松的不当使用对RDMGH有较高的影响。这可能会增加耐药病原体的出现,从而导致治疗失败并增加治疗费用。因此,建议遵循目前的循证指南。
{"title":"Drug Use Evaluation of Ceftriaxone in Ras-Desta Memorial General Hospital, Ethiopia.","authors":"Oumer Sada Muhammed,&nbsp;Beshir Bedru Nasir","doi":"10.2147/DHPS.S260364","DOIUrl":"https://doi.org/10.2147/DHPS.S260364","url":null,"abstract":"<p><strong>Background: </strong>Ceftriaxone is one of the most commonly used antibiotics due to its availability, wide spectrum of activity and low toxicity. However, irrational use of ceftriaxone is one of the current issues in most countries, especially developing ones.</p><p><strong>Objective: </strong>The aim of this study was to evaluate ceftriaxone utilization in different wards of Ras-Desta Memorial General Hospital (RDMGH) in Ethiopia.</p><p><strong>Methods: </strong>An institution-based retrospective cross-sectional study was conducted on randomly selected 1,079 patients who were admitted to RDMGH from May 2017 to April 2018. A structured data abstraction format was used to collect data from patients' medical chart. Micromedex® drug interaction checker was used to identify significant drug-drug interactions, and national and international guidelines were used to evaluate the appropriateness of ceftriaxone use. The data were analyzed by using SPSS version 20.0.</p><p><strong>Results: </strong>Among the 1,079 patients enrolled, ceftriaxone was utilized by 601 (55.7%) patients, and these patients were considered for evaluation of appropriateness and subsequent analysis. Among 601 patients, ceftriaxone was used for therapeutic purpose in 362 (60.2%) patients; of which, 359 (99.2%) were for empiric therapy and the rest 239 (39.8%) were for prophylaxis. In the majority of the patients, the dose of ceftriaxone was 2g/day 472 (78.6%) and for a duration of 2-7 days 409 (68.1%). Inappropriate use of ceftriaxone was observed among 237 (39.4%) patients with regard to indication, dose/frequency and duration. About half (49.3%) of the deviation from the guidelines was observed from surgical and gynecologic/obstetrics wards. Among the co-prescribed medications with ceftriaxone, ringer lactate, warfarin and heparin were found to have a significant drug-drug interaction.</p><p><strong>Conclusion: </strong>This study revealed that inappropriate use of ceftriaxone was high in RDMGH. This may increase the emergence of resistant pathogens which may lead to treatment failure and increase cost of therapy. Therefore, adherence to current evidence-based guidelines is recommended.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2020-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/DHPS.S260364","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38424156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
期刊
Drug, Healthcare and Patient Safety
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1